[go: up one dir, main page]

ECSP20001149A - Compuestos antiproliferativos y métodos para utilizarlos - Google Patents

Compuestos antiproliferativos y métodos para utilizarlos

Info

Publication number
ECSP20001149A
ECSP20001149A ECSENADI20201149A ECDI202001149A ECSP20001149A EC SP20001149 A ECSP20001149 A EC SP20001149A EC SENADI20201149 A ECSENADI20201149 A EC SENADI20201149A EC DI202001149 A ECDI202001149 A EC DI202001149A EC SP20001149 A ECSP20001149 A EC SP20001149A
Authority
EC
Ecuador
Prior art keywords
methods
compounds
antiproliferative compounds
compositions
dioxopiperidin
Prior art date
Application number
ECSENADI20201149A
Other languages
English (en)
Inventor
Gerald Artman
Timothy Kercher
Soraya Carrancio
Joshua Hansen
Mark Nagy
Lilly Wong
Brandon Whitefield
Paula Tavares-Greco
Daniel Pierce
James Carmichael
Brian E Cathers
Antonia Lopez-Girona
Hon-Wah Man
Rama Narla
Gordon Bray
Nanfei Zou
Xiaoling Lu
Matthew Correa
Courtney Havens
Matthew Alexander
Joseph Piccotti
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ECSP20001149A publication Critical patent/ECSP20001149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se proporciona 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperazin-1-il)-3-fluorobenzonitrilo, o un enantiómero, una mezcla de enantiómeros, un tautómero, o una sal farmacéuticamente aceptable de este, y métodos para tratar, prevenir o controlar el mieloma múltiple mediante el uso de dichos compuestos. También se proporcionan composiciones farmacéuticas que comprenden los compuestos y métodos de uso de las composiciones.
ECSENADI20201149A 2017-07-10 2020-01-08 Compuestos antiproliferativos y métodos para utilizarlos ECSP20001149A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530778P 2017-07-10 2017-07-10
US201762593185P 2017-11-30 2017-11-30
US201862675581P 2018-05-23 2018-05-23

Publications (1)

Publication Number Publication Date
ECSP20001149A true ECSP20001149A (es) 2020-02-28

Family

ID=63036419

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20201149A ECSP20001149A (es) 2017-07-10 2020-01-08 Compuestos antiproliferativos y métodos para utilizarlos

Country Status (28)

Country Link
US (5) US10357489B2 (es)
EP (2) EP3651766B1 (es)
JP (1) JP7258009B2 (es)
KR (1) KR102656934B1 (es)
CN (1) CN110869021B (es)
AU (2) AU2018301335B2 (es)
CA (1) CA3069138A1 (es)
CL (1) CL2020000060A1 (es)
CO (1) CO2020000193A2 (es)
DK (1) DK3651766T3 (es)
EC (1) ECSP20001149A (es)
ES (1) ES2992913T3 (es)
FI (1) FI3651766T3 (es)
HR (1) HRP20241553T1 (es)
HU (1) HUE069137T2 (es)
IL (1) IL271889B2 (es)
LT (1) LT3651766T (es)
MX (1) MX2023000085A (es)
PL (1) PL3651766T3 (es)
PT (1) PT3651766T (es)
RS (1) RS66162B1 (es)
SA (1) SA520411007B1 (es)
SG (1) SG11202000143PA (es)
SI (1) SI3651766T1 (es)
SM (1) SMT202400470T1 (es)
TW (2) TWI830576B (es)
WO (1) WO2019014100A1 (es)
ZA (1) ZA202000157B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830576B (zh) * 2017-07-10 2024-01-21 美商西建公司 抗增生化合物及其使用方法
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
SI3784663T1 (sl) * 2018-04-23 2023-11-30 Celgene Corporation Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
BR112020023756A2 (pt) * 2018-05-23 2021-02-09 Celgene Corporation tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila
IL282886B2 (en) 2018-11-08 2025-07-01 Juno Therapeutics Inc Methods and combinations for T-cell therapy and modulation
EA202191903A1 (ru) * 2019-01-09 2021-11-12 Селджин Корпорейшн Антипролиферативные соединения и вторые активные агенты для комбинированного применения
MX2021008295A (es) * 2019-01-09 2021-10-13 Celgene Corp Formas sólidas que comprenden (s)-4-(4-(4-(((2-(2,6-dioxopiperidin -3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperazin-1-il)-3-fl uorobenzonitrilo y sales del mismo, composiciones que comprenden y métodos de utilización del mismo.
EA202191904A1 (ru) * 2019-01-09 2021-10-04 Селджин Корпорейшн Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения
CN113677664B (zh) 2019-04-12 2025-04-04 C4医药公司 Ikaros和aiolos的三环降解物
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
CN115087448A (zh) 2019-10-21 2022-09-20 新基公司 使用2-(2,6-二氧代哌啶-3-基-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异二氢吲哚-1,3-二酮治疗血液恶性肿瘤的方法
JP2023504445A (ja) 2019-11-27 2023-02-03 キャプター セラピューティクス エス．エー． セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法
EP4065576A1 (en) 2019-11-27 2022-10-05 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
EP4095132A1 (en) 2020-01-20 2022-11-30 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, and pharmaceutical composition and use thereof
JP2023523545A (ja) * 2020-04-17 2023-06-06 エサイエント ファーマシューティカルズ，インコーポレイティド Ｍａｓ関連Ｇタンパク質受容体Ｘ４のモジュレーター、関連製品及びその使用方法
EP4142723A2 (en) * 2020-04-28 2023-03-08 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
US20230172923A1 (en) * 2020-04-30 2023-06-08 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
CA3182867A1 (en) 2020-06-25 2021-12-30 Aarif Ahsan Methods for treating cancer with combination therapies
CN113896711A (zh) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
DK4178548T3 (da) 2020-07-07 2024-08-19 Celgene Corp Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
CN115916768B (zh) * 2020-07-20 2024-12-24 江苏恒瑞医药股份有限公司 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
US20240294489A1 (en) 2020-08-03 2024-09-05 Captor Therapeutics S.A. Low molecular weight protein degraders and their applications
WO2022146151A1 (en) 2020-12-30 2022-07-07 Captor Therapeutics S.A. Novel compounds which bind to cereblon, and methods of use thereof
CN114685429A (zh) * 2020-12-31 2022-07-01 江苏恒瑞医药股份有限公司 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
JP2024520435A (ja) * 2021-05-27 2024-05-24 セルジーン コーポレーション 組み合わせ療法を用いて多発性骨髄腫を治療する方法
WO2022255889A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2022255890A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
JP2024528988A (ja) 2021-08-06 2024-08-01 セルジーン コーポレーション 改変タンパク質の選択的分解のための組成物および方法
CN116023319A (zh) * 2021-10-25 2023-04-28 英格尔医药科技(上海)有限公司 制备布瓦西坦的方法
EP4467536A4 (en) * 2022-01-19 2025-08-06 Jiangsu Hengrui Pharmaceuticals Co Ltd CRYSTALLINE FORM OF A SULFUR-CONTAINING ISOINDOLINE DERIVATIVE
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011312A1 (en) 1977-07-09 1980-05-28 LUCAS INDUSTRIES public limited company Road vehicle electrical systems
DE2848746A1 (de) 1978-11-10 1980-05-22 Wolfgang Arheiliger Dichtung fuer eine schwellenlose tuere mit drehfluegel
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ATE354655T1 (de) 1999-08-24 2007-03-15 Medarex Inc Humane antikörper gegen ctla-4 und deren verwendungen
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20060074103A1 (en) 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
KR101062513B1 (ko) 2006-02-17 2011-09-06 에프. 호프만-라 로슈 아게 5ｈｔ2/ｄ3 조절제로서의 벤조일-피페리딘 유도체
US8022214B2 (en) 2007-01-24 2011-09-20 Polyera Corporation Organic semiconductor materials and precursors thereof
ES2601131T3 (es) 2007-03-20 2017-02-14 Celgene Corporation Derivados de isoindolina 4'-O-sustituidos y composiciones que los comprenden y métodos de uso de los mismos
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
WO2010057087A1 (en) 2008-11-17 2010-05-20 Plextronics, Inc. Organic photovoltaic devices comprising substituted endohedral metallofullerenes
EP4331604B9 (en) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2381777A4 (en) 2008-12-12 2012-08-08 Ariad Pharma Inc AZAINDOL DERIVATIVES AS KINASEHEMMER
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
SG10202012179RA (en) * 2010-02-11 2021-01-28 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9346807B2 (en) 2010-09-14 2016-05-24 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
JP5728921B2 (ja) 2010-12-10 2015-06-03 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
SG10202108516PA (en) * 2012-08-09 2021-09-29 Celgene Corp Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
JP2015531776A (ja) 2012-09-04 2015-11-05 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3623011B1 (en) 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
US10273230B2 (en) 2014-07-25 2019-04-30 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
WO2016019386A1 (en) 2014-08-01 2016-02-04 Green Revolution Cooling, Inc. Controller for oil-cooled rack with multiple modes of operation
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
JP2018519353A (ja) 2015-07-08 2018-07-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのアリールスルタム誘導体
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
CN109415336B (zh) 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
US20190054097A1 (en) 2016-04-21 2019-02-21 Bioventures, Llc Compositions targeting senescent cells and the uses thereof
EP3507328B1 (en) 2016-08-30 2022-07-20 Dow Global Technologies LLC Method of attenuating concentration of acrolein
EP3522932A4 (en) 2016-10-10 2020-06-24 Cellerant Therapeutics, Inc. ISOCHINOLIDINOBENZODIAZEPINE (IQB) -1 (CHLORMETHYL) -2,3-DIHYDRO-1-H-BENZO [E] INDOL (CBI) DIMERS
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN109983027A (zh) 2016-10-20 2019-07-05 细胞基因公司 基于cereblon的可异二聚化嵌合抗原受体
CN110267659A (zh) 2016-12-08 2019-09-20 西奈山伊坎医学院 用于治疗cdk4/6介导的癌症的组合物和方法
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
TWI830576B (zh) * 2017-07-10 2024-01-21 美商西建公司 抗增生化合物及其使用方法
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CN109912655B (zh) 2017-12-13 2021-12-10 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
CN108690020A (zh) 2018-07-04 2018-10-23 清华大学 一种靶向降解bet蛋白的化合物及其应用
CN108794453A (zh) 2018-07-05 2018-11-13 清华大学 一种靶向降解fak蛋白的化合物及其应用

Also Published As

Publication number Publication date
ZA202000157B (en) 2021-08-25
US10357489B2 (en) 2019-07-23
CL2020000060A1 (es) 2020-07-31
LT3651766T (lt) 2024-12-10
TWI830576B (zh) 2024-01-21
HUE069137T2 (hu) 2025-02-28
TW201907923A (zh) 2019-03-01
US11185543B2 (en) 2021-11-30
JP2020526534A (ja) 2020-08-31
US20200253964A1 (en) 2020-08-13
KR20200026980A (ko) 2020-03-11
US20190282567A1 (en) 2019-09-19
SI3651766T1 (sl) 2025-02-28
IL271889B (en) 2022-11-01
CN110869021A (zh) 2020-03-06
TWI791552B (zh) 2023-02-11
KR102656934B1 (ko) 2024-04-16
PL3651766T3 (pl) 2025-03-03
EP4467143A3 (en) 2025-01-29
EP3651766B1 (en) 2024-09-11
SG11202000143PA (en) 2020-02-27
IL271889A (en) 2020-02-27
AU2018301335B2 (en) 2022-09-15
SA520411007B1 (ar) 2024-08-18
CA3069138A1 (en) 2019-01-17
DK3651766T3 (da) 2024-11-18
CO2020000193A2 (es) 2020-04-24
NZ760649A (en) 2025-02-28
JP7258009B2 (ja) 2023-04-14
US10675281B2 (en) 2020-06-09
RS66162B1 (sr) 2024-12-31
US12029738B2 (en) 2024-07-09
SMT202400470T1 (it) 2025-01-14
AU2022287569B2 (en) 2025-02-20
TW202319385A (zh) 2023-05-16
CN110869021B (zh) 2023-06-30
WO2019014100A1 (en) 2019-01-17
FI3651766T3 (fi) 2024-11-18
IL271889B2 (en) 2023-03-01
BR112020000442A2 (pt) 2020-07-21
EP4467143A2 (en) 2024-11-27
HRP20241553T1 (hr) 2025-01-17
AU2022287569A1 (en) 2023-02-02
PT3651766T (pt) 2024-11-25
ES2992913T3 (en) 2024-12-19
AU2018301335A1 (en) 2020-01-30
EP3651766A1 (en) 2020-05-20
MX2023000085A (es) 2023-02-09
US20190008852A1 (en) 2019-01-10
US20220280505A1 (en) 2022-09-08
US20240207255A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
ECSP20001149A (es) Compuestos antiproliferativos y métodos para utilizarlos
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2019001340A1 (es) Formas cristalinas de un inhibidor de magl.
MX388103B (es) Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2020007947A (es) Inhibidores de erbb/btk.
PE20211544A1 (es) Derivados de pirimidiniloxi benceno como herbicidas
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
ECSP18051143A (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
SV2016005313A (es) Derivados de carboxamida
CL2020002550A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون